Interleukin-13 -1112 C/T promoter polymorphism confers risk for COPD: a meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 23874547.
- Also identified by DOI 10.1371/journal.pone.0068222 and PMC identifier 3706578.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Interleukin (IL)-13, a T-helper type 2 cytokine, plays a critical role in the development of chronic obstructive pulmonary disease (COPD). This meta-analysis was performed to assess the association of IL-13 -1112 C/T promoter polymorphism with COPD susceptibility. Published case-control studies from Pubmed and China National Knowledge Infrastructure (CNKI) databases were retrieved. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Eight case-control studies in seven articles were included in this meta-analysis. Pooled effect size showed IL-13 -1112 C/T was associated with COPD susceptibility in a codominant genetic model (TT vs CT, OR: 1.82, 95% CI: 1.14-2.92 and TT vs CC, OR: 2.02, 95% CI: 1.10-3.72), indicating individuals with TT genotype had an increased risk for COPD compared with those with CT or CC genotype. According to ethnicity, results indicated IL-13 -1112 C/T was correlated with COPD susceptibility in Arabians (TT vs CT, OR: 2.94, 95% CI: 1.03-8.42 and TT vs CC, OR: 3.05, 95% CI: 1.08-8.59). Moreover, after excluding the study without Hardy-Weinberg equilibrium, the pooled results were robust and no publication bias was found in this study. This meta-analysis suggests IL-13 -1112 C/T promoter polymorphism is associated with the risk of COPD in Arabians.
Medical subject headings
- Interleukin-13
- Polymorphism, Single Nucleotide
- Promoter Regions, Genetic
- Pulmonary Disease, Chronic Obstructive